印戒细胞与晚期胃或食管胃交界腺癌一线化疗疗效
Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma.
作者信息
Lemoine Nathalie, Adenis Antoine, Bouche Olivier, Duhamel Alain, Heurgue Alexandra, Leteurtre Emmanuelle, Amela Eric, Salleron Julia, Hebbar Mohamed
机构信息
Department of Medical Oncology, University Hospital, Lille, France.
Department of Digestive Oncology, Oscar Lambret Centre, Lille, France.
出版信息
Anticancer Res. 2016 Oct;36(10):5543-5549. doi: 10.21873/anticanres.11138.
AIM
To evaluate the efficacy of first-line palliative chemotherapy, regarding the presence of signet ring cells (SRC).
PATIENTS AND METHODS
Retrospective analysis of consecutive patients with locally advanced or metastatic gastric or oesogastric junction adenocarcinoma who received first-line chemotherapy. Response to chemotherapy, progression-free survival (PFS) and overall survival (OS) were compared between SRC and non-SRC (NSRC) groups.
RESULTS
Two hundred and three patients were treated, with 57 (28%) having SRC adenocarcinoma. Objective response rate was significantly lower in SRC patients (5.3% vs. 28.1%, p=0.0004). PFS was not significantly different between SRC and NSRC patients (median=3.8 vs. 4.9 months, p=0.07). OS was significantly shorter in SRC patients (median=5.6 vs. 9.4 months, p<0.008). In multivariate analysis SRC was not an independent prognostic factor for OS (hazard ratio (HR)=1.28, p=0.15).
CONCLUSION
Patients with advanced SRC adenocarcinomas seemed to benefit less from chemotherapy, whereas the presence of SRC was not an independent survival prognostic factor.
目的
评估一线姑息化疗对印戒细胞（SRC）存在情况的疗效。
患者与方法
对接受一线化疗的局部晚期或转移性胃或食管胃交界腺癌连续患者进行回顾性分析。比较SRC组和非SRC（NSRC）组的化疗反应、无进展生存期（PFS）和总生存期（OS）。
结果
共治疗203例患者，其中57例（28%）为SRC腺癌。SRC患者的客观缓解率显著较低（5.3%对28.1%，p = 0.0004）。SRC患者和NSRC患者的PFS无显著差异（中位数分别为3.8个月和4.9个月，p = 0.07）。SRC患者的OS显著较短（中位数分别为5.6个月和9.4个月，p < 0.008）。多因素分析中，SRC不是OS的独立预后因素（风险比（HR）= 1.28，p = 0.15）。
结论
晚期SRC腺癌患者似乎从化疗中获益较少，而SRC的存在不是独立的生存预后因素。
Zotero 插件